Atgam

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Atgam
Generic name
EQUINE THYMOCYTE IMMUNE GLOBULIN
Manufacturer
Pharmacia & Upjohn Company LLC
Product type
PLASMA DERIVATIVE
SPL set ID
bd545ba1-2366-4df1-bd67-10dfd7632b54
SPL ID
a96a4454-b33e-409c-b58c-af3144b36dea
Version
21
Effective date
2024-06-18
Source export date
2026-11-13
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:02:30
Harmonized routes table
Harmonized routes
INTRAVENOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: ANAPHYLAXIS Anaphylaxis has been reported with the use of ATGAM. ATGAM can cause potentially life‑threatening anaphylaxis when injected intravenously. Monitor patients for signs and symptoms of anaphylaxis during infusion and for at least 24 hours after infusion [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning . Anaphylaxis has been reported with the use of ATGAM. ATGAM can cause potentially life‑threatening anaphylaxis when injected intravenously. Monitor patients for signs and symptoms of anaphylaxis during infusion and for at least 24 hours after infusion [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] .

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS • Anaphylaxis, which can be life-threatening, has been reported. To identify those at greatest risk, skin testing before treatment is strongly recommended. Discontinue ATGAM if anaphylaxis occurs. ( 5.1 ) • Monitor patients for signs and symptoms of cytokine release syndrome. ( 5.2 ) • Monitor patients for signs and symptoms of infusion-associated reactions. ( 5.3 ) • Monitor patients for signs and symptoms of serum sickness. ( 5.4 ) • Monitor and report any infection suspected to have been transmitted. ( 5.5 ) • Monitor patients for concurrent infection, including cytomegalovirus, Epstein-Barr virus, and herpes simplex virus infection. ( 5.6 ) • Do not administer live vaccines to patients about to receive, receiving, or after treatment with ATGAM due to a potential of uncontrolled viral replication in the immunosuppressed patient. ( 5.7 ) • Consider discontinuing therapy if severe and unremitting thrombocytopenia or neutropenia occurs. ( 5.8 ) • Monitor liver and renal function as clinically indicated and manage according to relevant clinical guidelines. ( 5.9 ) 5.1 Anaphylaxis Anaphylaxis has been reported with the use of ATGAM. Anaphylaxis is potentially life-threatening. Discontinue ATGAM if anaphylaxis occurs. G eneralized rash, tachycardia, dyspnea, and hypotension can be signs of an anaphylactic reaction. Skin Testing To identify those at greatest risk of systemic anaphylaxis, skin testing potential recipients is strongly recommended before commencing treatment. Consult an allergist for epicutaneous (prick) and intradermal testing and interpretation. Positive skin testing to ATGAM suggests clinical hyper sensitivity and increased risk of a systemic allergic reaction (including anaphylaxis) should the drug be dosed intravenously . In the event of a positive skin test, seriously consider alternative forms of therapy. The predictive value of this test has not been proven clinically, and allergic reactions such as anaphylaxis have occurred in patients whose skin tests were negative. It is important to note that skin testing does not inform risk of delayed hypersensitivity reactions such as serum sickness. Monitoring and Management of Anaphylaxis Administer ATGAM in a healthcare facility where a physician familiar with the treatment of potentially life-threatening allergic reactions is in attendance. Monitor patients for signs and symptoms of anaphylaxis during infusion and for at least 24 hours after infusion of ATGAM. Have epinephrine and emergency equipment available for treatment of acute allergic symptoms, should they occur. 5.2 Cytokine Release Syndrome Cytokine release syndrome has been reported with the use of ATGAM. Cytokine release syndrome can be fatal. Clinical signs may include fever, chills, headache, chest pain, hypotension, dyspnea, tachypnea, and edema. Monitor patients for signs and symptoms of cytokine release syndrome and manage according to relevant clinical guidelines. 5.3 Infusion-Associated Reactions Serious infusion-associated reactions have been reported with the use of ATGAM. Clinical signs associated with infusion-associated reactions include generalized rash, tachycardia, dyspnea, and hypotension. Monitor patients for signs and symptoms of infusion-associated reactions and manage according to relevant clinical guidelines. 5.4 Serum Sickness Serum sickness is a delayed hypersensitivity/immune reaction. Symptoms of serum sickness including rash, arthralgia, pyrexia, chills, and pain have been reported. Monitor patients for signs and symptoms of serum sickness and manage according to relevant clinical guidelines. 5.5 Transmissible Infectious Agents Because ATGAM is made from equine and human blood components, it may carry a risk of transmitting infectious agents, e.g., viruses and the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. Report any infection suspected to have been transmitted by this product to Pfizer Inc. at 1-800-438-1985. 5.6 Infections Due to the immunosuppressive effects of ATGAM, opportunistic infections (viral, bacterial and fungal) have been reported. Sepsis has also been reported. There is an increased risk of viral reactivation (e.g., cytomegalovirus [CMV], Epstein–Barr virus [EBV] infection, herpes simplex virus [HSV]). Monitor patients carefully for concurrent infection. 5.7 Immunizations Do not administer live vaccines to patients about to receive, receiving, or after treatment with ATGAM. Concomitant administration of ATGAM with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with ATGAM treatment. 5.8 Thrombocytopenia and Neutropenia Thrombocytopenia and neutropenia have been reported with the use of ATGAM. If thrombocytopenia occurs, consider platelet transfusions to maintain platelets at clinically acceptable levels. Consider discontinuing ATGAM if severe and unremitting thrombocytopenia or neutropenia occurs. 5.9 Hepatic and Renal Function Tests In patients with aplastic anemia and other hematologic abnormalities who have received ATGAM, abnormal test results of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine) have been observed. Monitor liver and renal functions as clinically indicated and manage according to relevant clinical guidelines .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most clinically significant adverse reactions are anaphylaxis, infection, thrombocytopenia, leukopenia, arthralgia, edema, bradycardia, and abnormal renal and liver function tests. The most common (incidence >10%) adverse reactions are pyrexia, chills, rash, thrombocytopenia, leukopenia, and arthralgia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of ATGAM has been evaluated in 367 patients with renal allograft rejection and 109 patients with aplastic anemia. The renal allograft rejection and aplastic anemia patients received a similar dosing regimen, and these data were pooled to obtain the frequencies listed in Tables 1 and 2 below. The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia, and arthralgia. Table 1. Adverse Reactions Occurring in ≥1% of Patients Who Received ATGAM Adverse Reaction Percentages are treatment-emergent all-causality events , Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms ATGAM Frequency (%) (N = 476) Pyrexia 39.5 Chills 26.5 Rash 25.6 Thrombocytopenia 21.6 Leukopenia 17.9 Arthralgia 17.2 Urticaria 9.2 Headache 5.3 Pruritus 4.6 Nausea 4.2 Infection 3.4 Vomiting 3.4 Thrombophlebitis 3.2 Hypertension 2.9 Hypotension 2.9 Diarrhea 2.9 Abdominal pain upper 2.7 Chest pain 2.7 Infusion site pain 2.1 Edema 2.1 Bradycardia 1.5 Back pain 1.5 Lymphadenopathy 1.3 Arteriovenous fistula thrombosis 1.3 Dizziness 1.1 Dyspnea 1.1 Tachycardia 1.1 Liver function test abnormal 1.0 Table 2. Adverse Reactions Occurring in <1% of Patients Who Received ATGAM Adverse Reaction Percentages are treatment-emergent all-causality events , Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms ATGAM Frequency (%) (N = 476) Convulsion 0.8 Pleural effusion 0.8 Night sweats 0.8 Serum sickness 0.6 Hyperglycemia 0.6 Stomatitis 0.6 Renal function test abnormal 0.6 Herpes simplex 0.4 Agitation 0.4 Hiccups 0.4 Proteinuria 0.4 Asthenia 0.4 Malaise 0.4 Wound dehiscence 0.4 Anaphylactic reaction 0.2 Encephalitis 0.2 Paresthesia 0.2 Renal artery thrombosis 0.2 Iliac vein occlusion 0.2 Laryngospasm 0.2 Pulmonary edema 0.2 Dermatitis allergic 0.2 Periorbital edema 0.2 Toxic epidermal necrolysis 0.2 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ATGAM. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infections and infestations: Sepsis, Hepatitis viral, Localized infection, Systemic infection (bacterial, viral, fungal). Blood and lymphatic system disorders: Anemia, Eosinophilia, Granulocytopenia, Hemolysis, Hemolytic anemia, Neutropenia, Pancytopenia Psychiatric disorders: Confusional state, Disorientation Nervous system disorders : Dyskinesia, Syncope, Tremor Cardiac disorders : Cardiac failure congestive Vascular disorders : Deep vein thrombosis, Vasculitis Respiratory, thoracic and mediastinal disorders : Apnea, Cough, Epistaxis, Oropharyngeal pain Gastrointestinal disorders : Abdominal pain, Gastrointestinal hemorrhage, Gastrointestinal perforation, Oral pain Skin and subcutaneous tissue disorders : Hyperhidrosis Musculoskeletal and connective tissue disorders : Flank pain, Muscle rigidity, Myalgia, Pain in extremity Renal and urinary disorders : Kidney enlargement, Kidney rupture, Renal failure acute Congenital, familial and genetic disorders : Aplasia General disorders and administration site conditions : Infusion site erythema, Infusion site swelling, Pain

adverse reactions table

<table width="65%"><caption>Table 1. Adverse Reactions Occurring in &#x2265;1% of Patients Who Received ATGAM</caption><col width="39%"/><col width="36%"/><tbody><tr><td styleCode="Rrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Adverse Reaction</content><footnote ID="_RefID0EHDAE">Percentages are treatment-emergent all-causality events</footnote><content styleCode="bold"><sup>,</sup></content><footnote ID="_RefID0EJDAE">Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms </footnote></paragraph></td><td align="center" styleCode="Rrule Toprule " valign="top"><paragraph><content styleCode="bold">ATGAM</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td align="center" styleCode="Rrule " valign="top"><paragraph><content styleCode="bold">Frequency (%)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">(N = 476)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>Pyrexia</paragraph></td><td align="center" styleCode="Rrule Toprule Botrule " valign="top"><paragraph>39.5</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Chills</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>26.5</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Rash</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>25.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Thrombocytopenia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>21.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Leukopenia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>17.9</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Arthralgia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>17.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Urticaria</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>9.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>5.3</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Pruritus</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>4.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Nausea</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>4.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Infection</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>3.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Vomiting</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>3.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Thrombophlebitis</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>3.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hypertension</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.9</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hypotension</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.9</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Diarrhea</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.9</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Abdominal pain upper</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.7</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Chest pain</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.7</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Infusion site pain</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.1</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Edema</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>2.1</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Bradycardia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.5</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Back pain</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.5</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Lymphadenopathy</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.3</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Arteriovenous fistula thrombosis</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.3</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Dizziness</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.1</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Dyspnea</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.1</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Tachycardia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.1</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Liver function test abnormal</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>1.0</paragraph></td></tr></tbody></table>

adverse reactions table

<table width="65%"><caption>Table 2. Adverse Reactions Occurring in &lt;1% of Patients Who Received ATGAM</caption><col width="38%"/><col width="37%"/><tbody><tr><td styleCode="Rrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Adverse Reaction</content><footnote ID="_RefID0EPJAE">Percentages are treatment-emergent all-causality events</footnote><content styleCode="bold"><sup>,</sup></content><footnote ID="_RefID0ERJAE">Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms</footnote></paragraph></td><td align="center" styleCode="Rrule Toprule " valign="top"><paragraph><content styleCode="bold">ATGAM</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule " valign="top"/><td align="center" styleCode="Rrule " valign="top"><paragraph><content styleCode="bold">Frequency (%)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"/><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph><content styleCode="bold">(N = 476)</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Toprule Botrule " valign="top"><paragraph>Convulsion</paragraph></td><td align="center" styleCode="Rrule Toprule Botrule " valign="top"><paragraph>0.8</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Pleural effusion</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.8</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Night sweats</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.8</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Serum sickness</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hyperglycemia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Stomatitis</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Renal function test abnormal</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.6</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Herpes simplex</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Agitation</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hiccups</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Proteinuria</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Asthenia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Malaise</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Wound dehiscence</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.4</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Anaphylactic reaction</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Encephalitis</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Paresthesia</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Renal artery thrombosis</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Iliac vein occlusion</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Laryngospasm</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Pulmonary edema</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Dermatitis allergic</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Periorbital edema</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Toxic epidermal necrolysis</paragraph></td><td align="center" styleCode="Rrule Botrule " valign="top"><paragraph>0.2</paragraph></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.